MURA(Delisted)
Mural OncologyยทNASDAQ
--
--(--)
MURA Profile
Mural Oncology Plc
A clinical-stage company focused on tumor immunotherapy
10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland
--
Mural Oncology plc is an Irish registered public limited company established in May 2017 as a private limited company. On August 21, 2023, the company was re-registered as a public limited company and changed its name to Mural Oncology plc. The company is a clinical-stage oncology company focused on discovering and developing immunotherapies that may meaningfully improve the lives of cancer patients. By leveraging the Company's core competencies in immune cell regulation and protein engineering, the Company has developed a range of novel investigational cytokine therapies designed to address areas of unmet need in a variety of cancer patients. The Company's lead product candidate, nemvaleukin alfa (" nemvaleukin "), is an investigational, engineered interleukin-2 (" IL-2 ") cytokine designed to capture and amplify the therapeutic benefits of high-dose recombinant human IL-2 (" rhIL-2 ") while mitigating its hallmark toxicity.
